Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.
Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE. Blecha JE, et al. Among authors: zavodovskaya m. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4026-9. doi: 10.1016/j.bmcl.2007.04.092. Epub 2007 Apr 29. Bioorg Med Chem Lett. 2007. PMID: 17502145 Free PMC article.
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.
Tolcher AW, Gordon M, Mahoney KM, Seto A, Zavodovskaya M, Hsueh CH, Zhai S, Tarnowski T, Jürgensmeier JM, Stinson S, Othman AA, Chen T, Strauss J. Tolcher AW, et al. Among authors: zavodovskaya m. J Immunother Cancer. 2023 Feb;11(2):e005267. doi: 10.1136/jitc-2022-005267. J Immunother Cancer. 2023. PMID: 36746510 Free PMC article. Clinical Trial.
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT. Shah MA, et al. Among authors: zavodovskaya m. J Immunother Cancer. 2021 Dec;9(12):e003580. doi: 10.1136/jitc-2021-003580. J Immunother Cancer. 2021. PMID: 34893523 Free PMC article. Clinical Trial.
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Bendell J, Sharma S, Patel MR, Windsor KS, Wainberg ZA, Gordon M, Chaves J, Berlin J, Brachmann CB, Zavodovskaya M, Liu J, Thai D, Bhargava P, Shah MA, Khan SA, Starodub A. Bendell J, et al. Among authors: zavodovskaya m. Oncologist. 2020 Nov;25(11):954-962. doi: 10.1634/theoncologist.2020-0474. Epub 2020 Sep 17. Oncologist. 2020. PMID: 32812320 Free PMC article. Clinical Trial.
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.
Yoshikawa AK, Yamaguchi K, Muro K, Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T, Mitani S, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Satoh T. Yoshikawa AK, et al. Among authors: zavodovskaya m. J Immunother Cancer. 2022 Jan;10(1):e003518. doi: 10.1136/jitc-2021-003518. J Immunother Cancer. 2022. PMID: 34992093 Free PMC article. Clinical Trial.
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
Ooki A, Satoh T, Muro K, Takashima A, Kadowaki S, Sakai D, Ichimura T, Mitani S, Kudo T, Chin K, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Yamaguchi K. Ooki A, et al. Among authors: zavodovskaya m. Sci Rep. 2022 Jun 30;12(1):11007. doi: 10.1038/s41598-022-13801-1. Sci Rep. 2022. PMID: 35773363 Free PMC article. Clinical Trial.
12 results